Rapid ventricular pacing alone or in combination with low-or intermediate-energy shocks has limited efficacy in cardioverting rapid ventricular tachycardia (VT) when delivered through two transvenous catheter electrodes. This prospective study determined the efficacy and safety of an algorithm that used a sequence of rapid ventricular pacing (RVP) and intermediate-energy (5 and 15 J) and high-energy (25 J) single, bidirectional shocks delivered by two transvenous catheter electrodes in conjunction with a cutaneous electrode in patients with sustained VT. The bidirectional shock was simultaneously delivered over two electrical vectors via a common right ventricular apical cathode and two anodes consisting of the superior vena caval catheter electrode and cutaneous patch. The electrical therapy delivered was determined by the cycle length of VT. Slow VT (cycle length>300 msec) was sequentially treated by RVP followed by incremental bidirectional shocks of 5, 15, and 25 J. Rapid VT (cycle length<300 msec) was treated with two incremental bidirectional shocks of 15 and 25 J. VT was reinduced to determine reproducibility of the algorithm for episodes that were successfully terminated. For patients in whom the primary algorithm failed, a second algorithm was used that excluded 5 and 15 J shocks and went directly to a 25 J shock. VT was reinduced twice and the secondary algorithm was evaluated. Thus, reproducibility of termination of VT with the primary and secondary algorithm was examined. Fifty episodes of slow VT and 40 episodes of rapid VT were induced in 22 patients (mean left ventricular ejection fraction 31 ± 14%). Six patients had rapid VT, nine patients had slow VT, and seven patients had both. Twelve patients were studied without and subsequently with antiarrhythmic therapy. Cardioversion by use of the primary algorithm was successful in 81 of 90 (90%) episodes of sustained VT with cycle lengths ranging from 170 to 550 msec. Forty-eight of 50 (96%) episodes of slow VT (mean cycle length 380 ± 60 msec) and 33 of 40 (83%) episodes of rapid VT (mean cycle length 242 ± 38 msec) were cardioverted by the primary algorithm. Antiarrhythmic drug therapy increased the frequency of VT termination by RVP (p = .005) and did not increase the mean energy threshold for successful cardioversion by transvenous shocks (p>.2). An unacceptable risk (30%) of accelerating VT or inducing ventricular fibrillation (VF) was observed with 5 and 15 J shocks.
ABSTRACT Rapid ventricular pacing alone or in combination with low-or intermediate-energy shocks has limited efficacy in cardioverting rapid ventricular tachycardia (VT) when delivered through two transvenous catheter electrodes. This prospective study determined the efficacy and safety of an algorithm that used a sequence of rapid ventricular pacing (RVP) and intermediate-energy (5 and 15 J) and high-energy (25 J) single, bidirectional shocks delivered by two transvenous catheter electrodes in conjunction with a cutaneous electrode in patients with sustained VT. The bidirectional shock was simultaneously delivered over two electrical vectors via a common right ventricular apical cathode and two anodes consisting of the superior vena caval catheter electrode and cutaneous patch. The electrical therapy delivered was determined by the cycle length of VT. Slow VT (cycle length>300 msec) was sequentially treated by RVP followed by incremental bidirectional shocks of 5, 15, and 25 J. Rapid VT (cycle length<300 msec) was treated with two incremental bidirectional shocks of 15 and 25 J. VT was reinduced to determine reproducibility of the algorithm for episodes that were successfully terminated. For patients in whom the primary algorithm failed, a second algorithm was used that excluded 5 and 15 J shocks and went directly to a 25 J shock. VT was reinduced twice and the secondary algorithm was evaluated. Thus, reproducibility of termination of VT with the primary and secondary algorithm was examined. Fifty episodes of slow VT and 40 episodes of rapid VT were induced in 22 patients (mean left ventricular ejection fraction 31 ± 14%). Six patients had rapid VT, nine patients had slow VT, and seven patients had both. Twelve patients were studied without and subsequently with antiarrhythmic therapy. Cardioversion by use of the primary algorithm was successful in 81 of 90 (90%) episodes of sustained VT with cycle lengths ranging from 170 to 550 msec. Forty-eight of 50 (96%) episodes of slow VT (mean cycle length 380 ± 60 msec) and 33 of 40 (83%) episodes of rapid VT (mean cycle length 242 ± 38 msec) were cardioverted by the primary algorithm. Antiarrhythmic drug therapy increased the frequency of VT termination by RVP (p = .005) and did not increase the mean energy threshold for successful cardioversion by transvenous shocks (p>.2). An unacceptable risk (30%) of accelerating VT or inducing ventricular fibrillation (VF) was observed with 5 and 15 J shocks.
Six episodes of VT that accelerated to VF were reinduced twice and treated by the secondary algorithm, proceeding directly to a 25 J shock. Each of these episodes was reproducibly terminated without acceleration by the 25 J shock. With the use of this approach a therapeutic algorithm that reproducibly terminated sustained VT transvenously without acceleration by a nonepicardial electrode system could be identified in 21 IMPLANTABLE DEVICES for termination of sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) are assuming an important role in the management of these disorders. 1-3 Clinical experience indicates that implantable antitachycardia pacemakers are applicable only to highly selected patients with recurrent VT. 1, 4 5The automatic implantable cardioverter/defibrillator is effective in reducing sudden arrhythmic death in a much wider patient population with VT and VF.6 While there are several limitations of the current device, the need for repeated high-energy shocks for arrhythmia termination and a thoracotomy to implant the epicardial patch electrode limit patient acceptance. Attempts to overcome these limitations led to the evaluation of low-energy transvenous cardioversion/defibrillation techniques.8-0 However, controlled studies demonstrated that low-energy transvenous shocks have only moderate efficacy for VT termination and are comparable in efficacy to pacing techniques. "' 12 Furthermore, pacing techniques are superior from the viewpoint of patient tolerance. VT cycle length is the major determinant of efficacy with both methods. VT episodes with shorter cycle lengths (<300 msec) are less frequently terminated with either method 1' 13 A recent report from our laboratory examined the efficacy of a combined pacing/lowand intermediateenergy transvenous shock algorithm in patients with VT. 14 In this study, pacing reduced the need for transvenous shocks in patients with VT cycle lengths above 270 msec. However, lowor intermediate-energy tranvenous shocks via two catheter electrodes (a unidirectional shock) were inadequate for reliable termination of fast VT episodes. Experimental studies have suggested that delivery of shock energy over two current pathways (a bidirectional shock) can reduce the energy required for arrhythmia termination. 5 16 We have recently demonstrated that bidirectional shocks delivered through nonepicardial electrodes do decrease energies required for successful termination in patients with recurrent VT, and increase efficacy to a limited extent. 17' 20 Lowor intermediate-energy bidirectional shocks remain inadequate to reliably terminate VT with this electrode system. 18 Currently, there remains a need to develop an effective and safe electrical algorithm with improved patient tolerance that can be applied through a nonepicardial electrode system. Thus, the purpose of this study was to prospectively evaluate the clinical efficacy, reliability, and safety of an algorithm incorporating rapid ventricular pacing (RVP) with intermediateand high-energy single bidirectional shocks delivered through a triple electrode array (two transvenous catheter electrodes and a cutaneous patch electrode) for termination of sustained VT irrespective of cycle length or concomitant antiarrhythmic drug therapy. Methods Patient selection. All patients entering this study satisfied the following selection criteria: (1) Each had recurrent sustained VT and was undergoing clinically indicated electrophysiologic studies (EPS). "Sustained" was defined as greater than 30 sec in duration or associated with immediate hemodynamic compromise. (2) None had suffered recent (<30 days) myocardial infarction. (3) All had sustained VT reproducibly induced during EPS. (4) All gave written informed consent to undergo transvenous cardioversion.
Twenty-two patients satisfied all inclusion criteria. There were 19 men and three women, with ages ranging from 41 to 81 (mean 65 + 9) years. All patients had organic heart disease with left ventricular ejection fractions ranging from 8% to 49% (mean 31 + 14%). Coronary artery disease was present in 20 patients and cardiomyopathy was present in two. Fifteen patients had a prior myocardial infarction and six had demonstrated left ventricular aneurysms. The details of clinical characteristics of the study population are shown in table 1.
Electrophysiologic procedures. Patients underwent the initial EPS in the nonsedated, postabsorptive state. Multipolar catheters were inserted by the standard percutaneous introducer techniques. A Medtronic 6880 temporary electrode catheter was used for transvenous cardioversion and pacing. This is a tripolar catheter electrode with a pair of bipolar electrodes at its distal end, each 1.25 cm2 in surface area, separated by an interelectrode distance of 5 mm, that is used for electrogram sensing and pacing. During cardioversion these electrodes become electrically common and form the cathode. Two electrically common proximal electrodes, each 1.25 cm2 in surface area, separated by 5 mm, comprised one anode and were 125 mm proximal to the distal electrode pair. The proximal electrodes were positioned at the junction of the superior vena cava and right atrium. Lead position was verified by fluoroscopy at the time of EPS. The electrodes were connected by three coil-wound, multifilar, drawn braised-strand, low-impedance wire electrical conductors in a coaxial configuration to three connector pins. The conductors were insulated by sleeves of polyurethane and an R2 skinpatch electrode (R2 Corp, Skokie, IL) with an area of 50 cm2 was placed over the left anterior chest wall just above the nipple to be used as the second anode. The connector pins at the proximal end of the catheter and the R2 patch were connected by a cable to a Medtronic model 5350 external cardioverter/ defibrillator. This device is a battery-operated generator capable of delivering graded energy shocks when the storage capacitor is discharged. It has sensing capabilities allowing shocks to be synchronized with the sensed electrogram. The energy output ranges from 0.03 to 28.0 J. The cardioverter can be interfaced with a programmed stimulator with the use of an external input that directly connects to the distal catheter electrodes for performance of programmed electrical stimulation and bipolar pacing. The ventricular threshold for programmed stimulation varied from 2 to 4 mA at pulse widths of 1 or 2 msec. The cardioversion shocks used in this study had a trapezoidal truncated exponential wave form with a 63% tilt. A single shock was delivered simultaneously across two current pathways, with the right ventricular apical cathode and superior vena cava anode comprising one pathway and the right ventricular apical cathode and left anterior cutaneous patch anode comprising the other pathway. Thus, the shock was bidirectional, i.e., it had two electrical vectors that were spatially distinct from each other. There was a total of 20 patients with CAD and two patients with CM. CAD = coronary artery disease; CM = cardiomyopathy; RB = right bundle branch block morphology; LB = left bundle branch block morphology; PM = polymorphic; IND = indeterminate.
Electrical therapy algorithm (figure 1). After induction of sustained VT, the mode of electrical therapy was selected on the basis of the tachycardia cycle length. The primary algorithm for slow VT (cycle length >300 msec) initially employed bursts of RVP in an asynchronous train of 15 paced stimuli. One burst was applied at each paced cycle length. The sequence of paced rates was equal to 90%, 80%, and 70% of the VT cycle length. Episodes of slow VT that were not terminated with RVP were exposed to three incremental bidirectional shocks (5, 15, and 25 J) synchronized to the right ventricular apical electrogram. Patients were lightly sedated with sodium pentothal before shocks were delivered. The primary algorithm for rapid VT episodes (cycle length s300 msec) employed two incremental bidirectional shocks (15 and 25 J) sequentially. In all instances, the protocol was terminated if the episode of VT was successfully cardioverted or after delivery of the 25 J shock. The protocol was designed to complete RVP and deliver the first 5 J shock within 1 min. For rapid VT the 15 J shock was delivered within 20 sec of induction of the arrhythmia. When required, incremental shocks were delivered at intervals of approximately 20 sec. External transthoracic cardioversion/defibrillation was performed when this final step of the protocol failed. Reproducible successful VT termination with the algorithm was demonstrated by reinduction of sustained VT with the same morphology and cycle length and with the identical termination algorithm. No attempt was made to reproduce failed attempts with the algorithm. For patients in whom the primary algorithm failed to terminate the tachycardia, sustained VT was reinduced during the same study and the secondary algorithm was used. The secondary algorithm eliminated both 5 and 15 J shocks for slow VT and eliminated 15 J shocks for rapid VT. In such cases, a single bidirectional 25 J shock was delivered and reproducible termination was evaluated.
Results
Clinical efficacy. A total of 102 consecutive episodes of inducible sustained VT in the 22 study patients were analyzed. Ninety episodes were treated with the primary algorithm and 12 with the secondary algorithm. In 15 patients, the initial episode of VT included in the study was induced in the drug-free state. In seven patients, the initial episode of VT included was induced during treatment with antiarrhythmic drugs. Six patients had only rapid VT inducible, nine patients had only slow VT inducible, and seven patients had both rates of VT induced during different EPS. Characteristics of the induced arrhythmias are shown in table 1. Eighty-one of 90 (90%) episodes of VT tested were cardioverted with the primary electrical algorithm. Sixty-nine of these 81 episodes were immediately terminated without acceleration. Twelve episodes were initially accelerated by the delivered therapy but were terminated by a subsequent step in the primary electrical algorithm; nine of 90 VT episodes (slow VT, two; rapid VT, seven) were accelerated and were not terminated by the algorithm; six of these latter nine episodes could be reinduced twice and all were terminated by a modified algorithm that eliminated the energy causing VT acceleration during the preceding unsuccessful cardioversion attempt and proceeded directly to the 25 J shock. Three episodes of rapid VT could not be reinduced due to patient intolerance for repeated induction of hemodynamically unstable VT. Overall, using the primary or secondary algorithm, RVP terminated 34 episodes of VT (33%), and transvenous bidirectional shocks terminated 59 episodes of VT (58%). Thirteen episodes of VF were induced by the primary algorithm and four (31 %) were terminated by it. The number of VT and VF terminations, failures, and accelerations at each step of the primary and modified algorithms is summarized in table 2. Termination of slow VT. The primary electrical algorithm terminated 48 of 50 (96%) episodes of slow VT (mean cycle length 380 + 60 msec) induced in 16 patients during 29 studies. As shown in figure 2, 27 of 29 initial episodes of VT were terminated by the primary algorithm. In 21 of these studies an episode of VT identical to the first episode was induced and reproducibly terminated. In six other studies VT was not reinduced because of hemodynamic instability. Intermediate-energy (5 or 15 J) shocks induced VF that was not terminated by a high-energy (25 J) shock in two patients. In these patients the algorithm was modified to eliminate 5 and 15 J shocks (secondary algorithm), and four subsequent episodes of VT with the same cycle length and morphology were reproducibly terminated without acceleration by 25 J shocks. The mean cycle lengths of tachycardias that were successfully terminated with the primary algorithm, failed to terminate with the primary algorithm, or were terminated by the secondary algorithm, were not significantly different.
Termination of rapid VT. The primary electrical algorithm converted 33 of 40 (83%) episodes of rapid VT (mean cycle length 242 ± 38 msec) induced in 13 patients. As shown in figure 3, 19 of 25 (76%) initial episodes of VT were terminated by the primary algorithm. Sixteen were immediately terminated and three episodes were accelerated initially by the 15 J shock but were later terminated by the 25 J shock. In 15 of these 19 studies an episode of VT identical to the first episode was reinduced and 14 of these episodes were terminated. Four initially successful terminations could not be reevaluated due to hemodynamic instability and patient intolerance. Six of the initial episodes of VT were not terminated by the primary algorithm because of acceleration to VF by 15 J shocks. Four of these episodes could be reinduced twice and were treated with the secondary algorithm that eliminated the 15 J shock, proceeding directly to a 25 J shock. All eight episodes of VT (100%) induced in these four patients were terninated without acceleration by a single 25 J shock. There were no differences in the cycle lengths of VT that were terminated with the primary algorithm, failed to terminate with the primary algorithm, or were terminated by the secondary algorithm. Safety. Overall, 21 VT accelerations (23%) were observed during 90 episodes of slow and rapid VT that were treated with the primary algorithm (table 2); 12 of these episodes were terminated by a subsequent step in the algorithm. Six of the remaining nine episodes of VT were reinduced and treated by the secondary algorithm that eliminated 5 and 15 J shocks. All were successfully terminated. Three episodes of rapid VT could not be reinduced because of patient intolerance for multiple VT inductions.
Nine (20%) slow VT episodes were accelerated by individual steps of the primary algorithm. Two of these episodes were accelerated twice. Seven of the nine accelerated slow VT episodes were terminated by a subsequent step of the algorithm. Three of the accelerations were induced by RVP with the pacing rate at 70% of VT cycle length; two were successfully terminated by 5 J shocks, and VF was induced by a 5 J shock in the remainder. Of the six remaining accelerated VT episodes, VT acceleration was induced in four episodes and VF was induced in two by 5 J shocks. One of the four VT accelerations was terminated by a 15 J shock, and two episodes required a 25 J shock. The remaining VT episode underwent further acceleration to VF after a 15 J shock. No episodes of slow VT were accelerated by 25 J shocks. The 25 J shock converted two episodes of VT and two episodes of VF to sinus rhythm, but it failed to convert two other episodes of VF. Thus, among the nine episodes of slow VT in which the primary algorithm accelerated VT or induced VF, two were terminated by 5 J shocks, one was terrninated by a 15 J shock, and four were terminated by 25 J shocks. In the two patients with VF that failed to convert, VT was reinduced and the algorithm was modified to exclude the accelerating energy (secondary algorithm). Both episodes were terminated twice by the secondary algorithm. The frequency of VT acceleration in slow VT was 5% with RVP, 47% with 5 J shocks, and 20% with 15 J shocks.
Ten episodes (25%) of rapid VT were accelerated by 15 J shocks, with VF being the induced rhythm in nine of the 10 episodes. Three of these episodes were terminated by the 25 J shock. Seven of these VT accelerations could not be terminated by 25 J shocks. All seven episodes had been accelerated to VF. Four of these seven episodes of VT could be reinduced and the algorithm was modified. All four were terminated twice. Figure 4 illustrates a representative episode of sustained fast VT in one patient in whom there was acceleration to VF induced by a 15 J shock (panel A); VF was not terminated by the 25 J shock (panel B). The tachycardia was then reinduced, the 15 J shock was eliminated, and tachycardia was now terminated without acceleration by the 25 J shock (panel C).
Reproducibility. The reproducibility of the electrical algorithms used in this study could be evaluated with a second VT induction for 42 successfully terminated episodes of VT; these included 23 episodes of slow VT in 13 patients and 19 episodes of fast VT in 13 patients. Reproducibility of the primary algorithm during the second episode was examined in 36 episodes of VT, and that of the secondary algorithm during six VT episodes. Forty-one of 42 (98%) successful terminations were reproduced during the second episode. Overall, the primary algorithm terminated VT twice in 14 of 22 patients (64%) and 35 of 36 episodes of VT (97%). In six of the remaining eight patients, the algorithm was modified to eliminate the accelerating energy, and termination for six episodes of VT could be evaluated a second time. Successful VT termination was achieved in each instance. VT could not be reinduced in one patient with rapid VT due to hemodynamic consequences. In the remaining patient, termination was reproduced twice while he was on drug therapy. Thus, serial EPS allowed selection of an algorithm that terminated sustained VT twice without acceleration in 21 of 22 (96%) patients and all slow and rapid episodes of VT that could be tested with the primary algorithm and/or secondary algorithms.
Effect of antiarrhythmic drug therapy. Twelve patients were studied in the drug-free state and subsequently underwent serial EPS during treatment with antiarrhythmic agents. The mean cycle length of sustained VT was 277 ± 70 msec during the control study and 324 + 65 msec during treatment with antiarrhythmic agents. The algorithm successfully terminated 32 of 35 (87%) episodes of VT at control studies and 61 of 67 (92%) episodes of VT at drug studies (p>.2). Five of 13 (38%) episodes of slow VT were terminated by RVP during control studies and 29 of 43 (67%) episodes of this type were terminated by RVP during treatment with antiarrhythmic agents (p = .005). The mean energies of bidirectional shocks successfully terminating VT episodes during control and drug studies were 18 and 18 J, respectively (p>.2), for episodes of fast VT and 15 and 13.5 J, respectively (p>.2) for episodes of slow VT. 606 
Discussion
The development of an electrical therapy algorithm for patients with VT that is clinically effective, safe, and reliable and that can be delivered through a nonepicardial lead system has been under intensive investigation for over a decade.9 t3 The basis of such elec-CIRCULATION VENTRICULAR FIBRILLATION '' 1 ' I" '11" 'I',1A .kv' jo) ;,W. ,k i trical algorithms has not been determined. The cycle length of induced VT is a major determinant of successful cardioversion with RVP as well as transvenous unidirectional or bidirectional shocks."1 13 We have previously reported comparable efficacy of bursts of RVP and low-energy (<2.7 J) transvenous shock energies. 12 These modalities have poor efficacy in episodes of fast VT with cycle lengths of less than 300 msec and are associated with a greater risk of acceleration." Intermediateor high-energy shocks have greater efficacy in fast VT. " On the basis of this available information, we developed an electrical therapy algorithm based on the VT cycle length. Pacing can be applied to slow VT episodes with a high chance of 13, 1 success. 14 Prior studies have indicated little or no additional yield with low-energy shocks after pacing methods have been applied.'4 These were eliminated from the algorithm. In pacing failures or in fast VT episodes, intermediate-energy shocks followed by high-energy shocks were used. Bidirectional shocks were preferred on the basis of prior clinical data obtained in our laboratory that demonstrated lower successful energy requirements and a limited increase (10% to 20%) in efficacy of cardioversion with shocks in the 10 to 20 J energy range. [17] [18] [19] [20] During bidirectional shocks, distribution of shock current along two electrical vectors has been demonstrated.'8 20 Preliminary studies have been conducted evaluating different cutaneous patch locations in the low and intermediate shock range; anterior or lateral locations are preferred but further study is necessary. '9 The results of this study demonstrate that effective and safe VT termination can be achieved with a nonepicardial electrode configuration in more than 96% of patients with sustained VT over a wide range of tachycardia cycle lengths varying fromi 150 to 550 msec. One patient in this study could not be retested with the secondary algorithm due to hemodynamic instability. Reproducibility testing was attempted at least once despite the malignant nature of the arrhythmia. With these limited test data, reliability of the algorithm was high. However, more stringent reproducibility testing will be warranted for long-term use of such algorithms. These results represent a marked improvement from previous trials in which limited efficacy and safety could be demonstrated, and reproducibility data were largely unavailable.9' 11, 14 Another important observation from this study is that the use of intermediate-energy shocks (5 to 15 J) with either unidirectional current flow, as in a prior study, or bidirectional current flow, as in this study, is associated with an unacceptably high incidence of VT Vol. 76, No. 3, September 1987 acceleration or degeneration into VF (30%). 14, 18 VT acceleration or failure to terminate was not observed with a 25 J bidirectional shock in this study. In contrast to pacing techniques with which increasing pacing train length or rate can increase efficacy as well as frequency of VT acceleration, increasing shock energies beyond 20 J increases efficacy and reduces the incidence of VT acceleration.20 The explanation for this observation can be inferred from the mechanisms underlying transvenous cardioversion.21-23 Results of cardiac mapping indicate that even low-energy (>0.5 J) transvenous shocks can produce immediate depolarization of distant ventricular regions and conduction delay/block in reentrant VT circuits, provided excitable tissue is available.
Thus, QRS synchronized transvenous shocks termninate VT by producing conduction delay in myocardium activated later, i.e., in electrical diastole, resulting in instability or block in the circuit leading to termination. VT acceleration is due to modification of diastolic conduction without conduction block, resulting in an altered but stable circuit with a shorter revolution time, which is probably related to concomitant changes in refractoriness of the adjoining tissues. Thus, it is not surprising that intermediate-energy shocks modify conduction with a high incidence of acceleration (up to 47% in this study), but higher energy shocks prevent this complication by producing widespread high-degree conduction block. The same principle at different absolute shock energy levels should be applicable to all electrode configurations for VT cardioversion. Furthermore, since the "excitable" gap may be least prominent or even absent in rapid VT, high-energy shocks would be necessary to depolarize relatively refractory tissues in such a circuit to produce interruption of conduction. Thus, on the basis of this study, the use of RVP in combination with high-energy (>25 J) bidirectional shocks would maximize efficacy and minimize complications.
The need for high-energy shocks in an electrical therapy algorithm could be considered in direct conflict with the goal of reducing patient exposure to this uncomfortable form of therapy. However, an alternative approach exists and should be considered. Pacing techniques used in this study as the first line oftreatment for slower episodes of VT reduced the need for highenergy shocks by 63%. Only three attempts at burst pacing were used in this algorithm. A greater number of attempts or other modifications in pacing algorithms could further iipprove the yield with this method. 14, 24 Innovations in pacing techniques for VT termination are warranted and will improve patient tolerance. Moreover, concomitant antiarrhythmic therapy can slow fast VT episodes, making them more amenable to pacing and often reducing the frequency of VT events, thereby limiting the need for cardioversion. Importantly, in this study antiarrhythmic drug therapy did not increase the mean shock energy required for VT cardioversion, and should not impact adversely on the efficacy of transvenous shocks.
This algorithm can be considered for temporary use in an emergent clinical situation and for permanent use in implantable devices for patients with recurrent VT. The results of this study have particularly important implications for the next generation of implantable cardioverters/defibrillators, which will employ programmable pacing algorithms and shock energies. Moreover, transvenous lead systems may be considered for selected patients. Although the absolute magnitude of energies required will vary according to lead configurations, it appears that internediate energies have a propensity to accelerate VT and must be defined for the system that is implanted. This is particularly germane to nonepicardial lead systems, which have limited efficacy in VF. Avoidance of intermediate energies can reduce the risk of this complication. A related issue is whether spontaneous arrhythmic events start as VT or VF. Currently available data suggest that VT is frequently the initial rhythm, and thus this algorithm, particularly in its modified form, could be applicable.25-27 A low-energy implantable cardioverter has been used in highly selected patients with recurrent VT with some efficacy but limited reliability in the automatic mode. 10 We would expect that devices using this algorithm would be applicable to a wider patient population with recurrent VT than current antitachycardia pacemakers or low-energy cardioverters, and would have greater safety and reliability. Rapid degeneration into VF or spontaneous VF would require demonstration of reproducible defibrillation with a nonepicardial electrode system. This may be feasible in selected patients. We have recently demonstrated reproducible and reliable defibrillation of VF with an implanted automatic implantable cardioverter/defibrillator in conjunction with a triple nonepicardial electrode system in a patient with recurrent VT/VF. 8 29 Many other patients may still require the use of an epicardial electrode system. However, selection of a nonepicardial lead system could be feasible for many patients. The use of multiple or higher energy shocks delivered sequentially, as in the current implantable defibrillator, could further enhance its efficacy in VF. Alternative transvenous lead/subcutaneous electrode configurations or larger catheter electrode surface areas with better tissue contact could also be considered in future developments to improve efficacy in VF. Current experimental data suggest that the use of three sequential shocks does not offer significant advantages over single or two sequential bidirectional shocks. 16 In conclusion, cardioversion of sustained VT is feasible over the entire range of VT cycle lengths with a nonepicardial lead configuration. However, high-energy shocks are essential for reliable VT cardioversion, and intermediate-energy shocks should be avoided with this lead configuration. Moreover, the use of RVP and concomitant antiarrhythmic drug therapy can reduce patient exposure to painful shocks and may facilitate patient management. Accordingly, a device that incorporates RVP and 25 J bidirectional shocks delivered by two transvenous catheters and one subcutaneous or submuscular electrode should receive further consideration for permanent implantation.2829
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